Pet care shines as growth driver

Boehringer Ingelheim reported strong financial results for 2025, with net revenue rising 7.3% to €27.8 bn. According to a press release, the Human Pharma division led growth, generating €22.7 bn, up 7.4%. Key products performed robustly: Jardiance, which treats diabetes, heart failure and chronic kidney disease, climbed 8.7% to €8.8 bn, whilst Ofev, used for pulmonary fibrosis and progressive lung disease, grew 5.4% to €3.8 bn. Research and development investment reached a record €6.4 bn, representing 22.9% of total revenue. The company also successfully launched two new medicines ‒ Hernexeos, an oral treatment for lung cancer, and Jascayd, the first new idiopathic pulmonary fibrosis therapy in over a decade ‒ in the United States and China.

Boehringer Ingelheim's Animal Health division demonstrated strong resilience in 2025, with revenue climbing 6.5% to…